Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy

Cereda, Cw; Zecca, C; Mazzucchelli, L; Valci, L; Staedler, C; Bassetti, Cl; Gobbi, C (2013). Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy. Multiple sclerosis journal, 19(6), pp. 820-3. London: Sage 10.1177/1352458512461969

Full text not available from this repository.

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-α antagonist (anti-TNF-α) acting as a soluble TNF-α receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -α antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy confirmed the inflammatory demyelinating nature of the lesions. The clinical presentation is unusual due to the severity of the disease process, requiring decompressive hemicraniotomy with a clinically favorable outcome.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
UniBE Contributor:	Bassetti, Claudio L.A.
ISSN:	1352-4585
Publisher:	Sage
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:39
Last Modified:	02 Mar 2023 23:21
Publisher DOI:	10.1177/1352458512461969
PubMed ID:	23069873
Web of Science ID:	000318637900018
URI:	https://boris.unibe.ch/id/eprint/15882 (FactScience: 223376)